Chewy's $600M Guidance Raise Is Really About the Vet Clinics

Chewy raised its fiscal 2026 net sales guidance to $13.6–$13.8 billion on April 9, roughly $600 million above Wall Street consensus, and sent shares up about 13% on the day. Management pointed squarely at Chewy Vet Care as the fastest-growing segment driving the raise and told investors to expect zero price inflation across the 2026 plan. Both signals matter far more than the headline number.

What Happened

One day after announcing its $125-million-run-rate acquisition of Modern Animal, Chewy updated its outlook for both Q1 and full-year fiscal 2026. The company guided Q1 2026 revenue to $3.33–$3.36 billion and adjusted EPS to $0.40–$0.45, versus Street consensus of roughly $0.34. Full-year net sales are now expected at $13.6–$13.8 billion, topping the roughly $13.0 billion consensus by approximately $600 million. Shares closed up around 13% at roughly $26.50.

CEO Sumit Singh attributed the raise to four compounding drivers. Chewy Vet Care, which added 10 new locations in fiscal 2025 to reach 18 practices across five states, is now the fastest-growing segment by net sales per active customer and, per Singh, is functioning as a customer-acquisition tool that strengthens ties with high-value buyers. AI-driven operational efficiencies are expected to deliver a “low tens of millions” benefit in 2026, stepping up to roughly $50 million or more in annualized savings by 2027. The pending Modern Animal acquisition contributes partial-year revenue once the deal closes, expected in Q2 fiscal 2026. And the next-generation fulfillment center in Houston continues to ramp.

Two details in the commentary deserve more attention than they have gotten. First, the plan assumes zero price inflation in 2026, with active customer growth held at low single digits and net adds consistent across quarters. Second, Q1 was explicitly framed as the lowest-growth quarter of the year, meaning the raise is back-end weighted on services and health contribution.

The board also authorized a $500 million increase to Chewy’s share repurchase authorization alongside the Modern Animal announcement.

Why It Matters

The Modern Animal deal was the M&A headline. The April 9 guidance update is the investor message underneath it, and it reframes what Chewy is actually doing.

1. Chewy is rewriting its growth equation around services, not GMV. For most of its public life, Chewy has been underwritten as an e-commerce story with margin expansion tied to Autoship mix and private label. The FY2026 raise puts Chewy Vet Care, pharmacy, insurance, and health at the center of the growth narrative. Singh’s explicit framing of CVC as “the fastest-growing segment by net sales per active customer” is the kind of language analysts anchor models on. Expect segment disclosure to follow.

2. “Vet care as CAC tool” is the part operators should sit with. Management isn’t positioning the clinic network primarily as a vet-services P&L. It is positioning it as a customer-acquisition and retention mechanism for the commerce business. That reframes the Modern Animal acquisition: Chewy did not pay for 29 clinics and 100,000 member families because veterinary services is a better standalone business than e-commerce. They paid for it because each member family is worth more lifetime spend across food, pharmacy, and supplements than any paid-acquisition channel can deliver at comparable cost. This is the same logic that turned Costco into a membership business that happens to sell groceries.

3. Zero price inflation in 2026 is a real signal, not a boilerplate assumption. Chewy moves an enormous share of the U.S. pet product mix. Telling investors there will be no pricing this year is a revealed preference about what the platform will absorb and what it will pass to brands. Suppliers facing higher COGS from tariffs, ingredients, or packaging now have a data point on who eats the compression. With the USTR Section 301 comment deadline on April 15, the timing is not incidental. Challenger brands that rely on Chewy for scale should pressure-test their 2026 margin models against a platform that has publicly committed to flat shelf prices.

4. The buyback is a tell. A $500 million authorization bump alongside a guidance raise, from a company that is simultaneously acquiring a 29-clinic network, is management signaling that capital returns and vertical integration are not competing priorities. That is only true if services-led growth is compounding fast enough to fund both.

What to Watch

Q1 2026 earnings report (late May / early June). This is where the story either holds or cracks. Watch for any breakout disclosure on Chewy Vet Care revenue, active member families, or per-customer net sales lift. If Chewy starts reporting CVC as a distinct line, the services-led thesis becomes investable in a different way.

Whether the zero-inflation guide holds through Q2. If Section 301 hearings (April 28–May 1 and May 5–8) escalate costs for pet-adjacent categories like plastics, processed food, and chemicals, Chewy’s flat-pricing commitment becomes harder to maintain. Any mid-year revision would ripple through every brand forecasting pass-through.

Competitive response from Petco and Mars. Petco is already rebuilding its customer analytics and loyalty stack ahead of a 2026 re-launch, and Mars owns Banfield, VCA, and BluePearl but has no direct commerce engine. If either accelerates a services-plus-commerce move in response, it will confirm that Chewy has redrawn the category’s competitive frame.

Modern Animal close and integration milestones. Q2 fiscal 2026 close is the working assumption. Any delay, any change to the $125 million run-rate figure, or any early unified-account announcements will move the services thesis in either direction.

Related Analysis

• Chewy Is Buying Modern Animal — and Betting That Owning the Vet Is the Moat
• Snout Raises $110M to Finance Vet Bills as Pet Care Costs Surge

Source: Chewy Investor Relations